Rosetta Genomics has selected Nanogen’s MGB Probe technology for its line of miRNA-based diagnostics. The company expects to lauch the first product in 2008.
Rosetta will combine the technical performance advantages of MGB Probe technology with its miRNA biomarkers to create a line of quantitative real-time PCR diagnostic tests for various cancers.